SHANGHAI – Luqa Pharmaceuticals' $15 million series A financing will boost efforts to acquire, develop and commercialize products for Chinese patients in the aesthetics and quality-of-life markets. Products include pharmaceuticals and devices for both the reconstructive and elective plastic surgery market.